Wire · operational-macro
Psychedelic therapies ride wave of public favor into FDA hearing
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
The FDA is holding a public hearing on psychedelic drug development, supported by key stakeholders including patients, healthcare providers, and government agencies. New leadership experienced in psychedelics and recent regulatory guidance suggest approval of treatments like Compass Pathways' psilocybin candidate is likely by 2027.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it between 14 Sep 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
You can capitalise on the loosening FDA rules for psychedelic therapies as new leadership prioritises mental health treatments. Prepare for market entry by building clinical and regulatory expertise around psilocybin and related compounds now.
◆ Coverage
3 sources · first reported 14 Sep 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics